yahoo_financeOriginal article
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Phase 2QRX003Positive
AI Analysis
Summary
Quoin Pharmaceuticals received FDA IND clearance to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome. This regulatory milestone allows the company to proceed with clinical testing of the investigational drug.
Clinical Trial Data
Phase
Phase 2
Outcome Details
IND clearance received to initiate Phase 2 study
Importance:6/10
Sentiment:
0.70
FDA approvalIND clearancePhase 2rare diseasedermatology
Related Companies
Read the original article
Published by yahoo_finance on July 9, 2026 12:30 PM